Related references
Note: Only part of the references are listed.Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms
Jeremy Yuen-Chun Teoh et al.
PROSTATE (2022)
Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer
Darren M. C. Poon et al.
CANCERS (2022)
Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study
Chris Wong et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2022)
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses
Jiun-Ruey Hu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study
Chi-fai Ng et al.
SCIENTIFIC REPORTS (2020)
Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study
Jong-Mi Seong et al.
JOURNAL OF CANCER (2020)
Lipid Status During Combined Treatment in Prostate Cancer Patients
Edyta Wolny-Rokicka et al.
AMERICAN JOURNAL OF MENS HEALTH (2019)
Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2
Thiago Gagliano-Juca et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer
K. Mitsuzuka et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men
L. H. Wang et al.
ANDROLOGY (2016)
Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer
Ada S. Cheung et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective
Jeremy Yuen Chun Teoh et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2016)
Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer
Jeremy Yuen Chun Teoh et al.
AGING MALE (2015)
Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population
Jeremy Y. C. Teoh et al.
BJU INTERNATIONAL (2015)
Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population
Jeremy Yuen Chun Teoh et al.
JOURNAL OF DIABETES (2015)
Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?
Daniel M. Seible et al.
UROLOGY (2014)
Analysis of the Lipid Profile and Atherogenic Risk during Androgen Deprivation Therapy in Prostate Cancer Patients
C. Salvador et al.
UROLOGIA INTERNATIONALIS (2013)
Impact of Androgen Deprivation Therapy on Weight Gain Differs by Age in Men with Nonmetastatic Prostate Cancer
Narhari Timilshina et al.
JOURNAL OF UROLOGY (2012)
Fasting Blood Glucose and Lipid Profile Alterations following Twelve-Month Androgen Deprivation Therapy in Men with Prostate Cancer
Hasan S. Saglam et al.
SCIENTIFIC WORLD JOURNAL (2012)
Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks
Juan-Jie Bo et al.
ASIAN JOURNAL OF ANDROLOGY (2011)
Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy
E. J. Hamilton et al.
CLINICAL ENDOCRINOLOGY (2011)
The Effects of Androgen Deprivation Therapy on Lipid Metabolism and Body Composition in Japanese Patients with Prostate Cancer
Kazumasa Torimoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Associations of Visceral and Subcutaneous Fat Areas With the Prevalence of Metabolic Risk Factor Clustering in 6,292 Japanese Individuals The Hitachi Health Study
Yumi Matsushita et al.
DIABETES CARE (2010)
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Michel Bolla et al.
LANCET ONCOLOGY (2010)
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
Jason E. Faris et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2010)
Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer
Ithaar H. Derweesh et al.
BJU INTERNATIONAL (2007)
The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters
Jennifer Yannucci et al.
JOURNAL OF UROLOGY (2006)
Insulin sensitivity during combined androgen blockade for prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Does measurement site for visceral and abdominal subcutaneous adipose tissue alter associations with the metabolic syndrome?
JL Kuk et al.
DIABETES CARE (2006)
Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy
M. Braga-Basaria et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2006)
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma
H Lee et al.
CANCER (2005)
Antiandrogenic therapy can cause coronary arterial disease
KC Chen et al.
INTERNATIONAL JOURNAL OF UROLOGY (2005)
The influence of androgen deprivation therapy on metabolism in patients with prostate cancer
T Nishiyama et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia
F Dockery et al.
CLINICAL SCIENCE (2003)
Osteoporosis during androgen deprivation therapy for prostate cancer
MR Smith
UROLOGY (2002)